Investigations on the 4‐Quinolone‐3‐Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid‐2 Receptor Ligands through a Bioisosteric Approach

Three heterocyclic systems were selected as potential bioisosteres of the amide linker for a series of 1,6‐disubstituted‐4‐quinolone‐3‐carboxamides, which are potent and selective CB2 ligands that exhibit poor water solubility, with the aim of improving their physicochemical profile and also of clarifying properties of importance for amide bond mimicry. Among the newly synthesized compounds, a 1,2,3‐triazole derivative (1‐(adamantan‐1‐yl)‐4‐[6‐(furan‐2‐yl)‐1,4‐dihydro‐4‐oxo‐1‐pentylquinolin‐3‐yl]‐1H‐1,2,3‐triazole) emerged as the most promising in terms of both physicochemical and pharmacodynamic properties. When assayed in vitro, this derivative exhibited inverse agonist activity, whereas, in the formalin test in mice, it produced analgesic effects antagonized by a well‐established inverse agonist. Metabolic studies allowed the identification of a side chain hydroxylated derivative as its only metabolite, which, in its racemic form, still showed appreciable CB2 selectivity, but was 150‐fold less potent than the parent compound.

[1]  F. Corelli,et al.  Regioselective functionalization of quinolin-4(1H)-ones via sequential palladium-catalyzed reactions , 2011 .

[2]  M. Frosini,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. , 2011, Journal of medicinal chemistry.

[3]  R. Moaddel,et al.  Development and characterization of immobilized cannabinoid receptor (CB1/CB2) open tubular column for on-line screening. , 2011, Analytical biochemistry.

[4]  N. Meanwell Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[5]  E. Dreassi,et al.  2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. , 2010, European journal of medicinal chemistry.

[6]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[7]  M. Cascio,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. , 2010, Journal of medicinal chemistry.

[8]  P. Diaz,et al.  Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain , 2010, Anesthesia and analgesia.

[9]  M. Cascio,et al.  The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice , 2010, British journal of pharmacology.

[10]  M. Cascio,et al.  In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. , 2010, Pharmacological research.

[11]  B. Kuhn,et al.  A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of medicinal chemistry.

[12]  Paul F. Smith,et al.  Cannabinoids in the treatment of cancer. , 2009, Cancer letters.

[13]  R. Dolle,et al.  Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands. , 2009, Current pharmaceutical design.

[14]  E. Dreassi,et al.  Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. , 2009, European journal of medicinal chemistry.

[15]  D. Tulshian,et al.  Constitutive activity of cannabinoid‐2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242 , 2009, British journal of pharmacology.

[16]  H. Hsieh,et al.  Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. , 2009, Journal of medicinal chemistry.

[17]  M. Bifulco,et al.  Endocannabinoid system modulation in cancer biology and therapy. , 2009, Pharmacological research.

[18]  S. Zographos,et al.  Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case , 2009 .

[19]  P. Anand,et al.  Targeting CB2 receptors and the endocannabinoid system for the treatment of pain , 2009, Brain Research Reviews.

[20]  L. Alcaraz,et al.  Antagonists of the P2X(7) receptor. From lead identification to drug development. , 2009, Journal of medicinal chemistry.

[21]  R. Pertwee,et al.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.

[22]  A. Idris Role of cannabinoid receptors in bone disorders: alternatives for treatment. , 2008, Drug news & perspectives.

[23]  Vinod Kumar,et al.  Unique Versatility of Ionic Liquids as Clean Decarboxylation Catalyst Cum Solvent: A Metal‐ and Quinoline‐Free Paradigm towards Synthesis of Indoles, Styrenes, Stilbenes and Arene Derivatives under Microwave Irradiation in Aqueous Conditions , 2008 .

[24]  Chong-Hwan Chang,et al.  Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. , 2008, Journal of medicinal chemistry.

[25]  S. Hitchcock,et al.  Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists. , 2008, Journal of Medicinal Chemistry.

[26]  L. Botta,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. , 2008, Journal of medicinal chemistry.

[27]  C. Tintori,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. , 2008, Journal of medicinal chemistry.

[28]  Christine Chabot,et al.  Sterically biased 3,3-sigmatropic rearrangement of chiral allylic azides: application to the total syntheses of alkaloids. , 2008, The Journal of organic chemistry.

[29]  M. Camilleri,et al.  Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects , 2008, Gut.

[30]  V. Adhami,et al.  Cannabinoids for cancer treatment: progress and promise. , 2008, Cancer research.

[31]  F. Mach,et al.  Cannabinoid receptors in acute and chronic complications of atherosclerosis , 2008, British journal of pharmacology.

[32]  P. Pacher,et al.  Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning , 2008, British journal of pharmacology.

[33]  A. Hohmann,et al.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.

[34]  N. Stella,et al.  CB2 receptor‐mediated migration of immune cells: it can go either way , 2008, British journal of pharmacology.

[35]  M. Cascio,et al.  The 1,2,3-triazole ring as a peptido- and olefinomimetic element: discovery of click vanilloids and cannabinoids. , 2007, Angewandte Chemie.

[36]  Manfred Kansy,et al.  High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.

[37]  R. Pertwee Cannabinoids and Multiple Sclerosis , 2007, Molecular Neurobiology.

[38]  M. García-Arencibia,et al.  Cannabinoids and Neuroprotection in Basal Ganglia Disorders , 2007, Molecular Neurobiology.

[39]  K. Valenzano,et al.  The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. , 2007, Current medicinal chemistry.

[40]  Kazuo Kitaura,et al.  Pair interaction energy decomposition analysis , 2007, J. Comput. Chem..

[41]  J. Crow,et al.  The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset , 2006, Journal of neurochemistry.

[42]  Li Di,et al.  Biological assay challenges from compound solubility: strategies for bioassay optimization. , 2006, Drug discovery today.

[43]  J. J. Goodwin Rationale and benefit of using high throughput solubility screens in drug discovery. , 2006, Drug discovery today. Technologies.

[44]  A. Fura,et al.  Role of pharmacologically active metabolites in drug discovery and development. , 2006, Drug discovery today.

[45]  Jay S. Fine,et al.  A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[46]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[47]  G. Caliendo,et al.  A suitable 1,2,4-oxadiazoles synthesis by microwave irradiation. , 2004, Bioorganic & medicinal chemistry letters.

[48]  W. Humphreys,et al.  Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. , 2004, Journal of medicinal chemistry.

[49]  K. Valko,et al.  Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. , 2004, Journal of chromatography. A.

[50]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[51]  A. Galetin,et al.  Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies , 2003, Drug metabolism reviews.

[52]  Z. Tuba,et al.  Synthesis of steroidal diacyl hydrazines and their 1,3,4-oxadiazole derivatives , 2002, Steroids.

[53]  R. Pertwee,et al.  Cannabinoid receptors and their ligands , 2002, European Neuropsychopharmacology.

[54]  H. Iwamura,et al.  In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[55]  J. Owen,et al.  A Novel and Efficient Synthesis of 2,3-Dichloroquinoline , 2000 .

[56]  R. Pertwee,et al.  Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.

[57]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[58]  Robin Taylor,et al.  Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles , 1997 .

[59]  Gerhard Klebe,et al.  Oxygen and Nitrogen in Competitive Situations: Which is the Hydrogen‐Bond Acceptor? , 1996 .

[60]  R. F. Westbrook,et al.  The formalin test: scoring properties of the first and second phases of the pain response in rats , 1995, Pain.

[61]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[62]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[63]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[64]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[65]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[66]  K. Morokuma,et al.  The origin of hydrogen bonding. An energy decomposition study , 1977 .

[67]  Kazuo Kitaura,et al.  A new energy decomposition scheme for molecular interactions within the Hartree‐Fock approximation , 1976 .

[68]  W. E. Smith Formylation of aromatic compounds with hexamethylenetetramine and trifluoroacetic acid , 1972 .

[69]  R. Pertwee,et al.  Pharmacological actions of cannabinoids. , 2005, Handbook of experimental pharmacology.

[70]  Guomin Yao,et al.  Adamantylchlorocarbene: characterization and rearrangement to chlorohomoadamant-3-ene , 1999 .